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Introduction. Multidrug resistance of Plasmodium falciparum is spreading throughout Africa. This has posed major challenges to
malaria control in sub-Saharan Africa. Objective. The aim of the study was to evaluate the eﬃcacy of artemether-lumefantrine
for the treatment of uncomplicated Plasmodium falciparum malaria in North Ethiopia. Methods. This prospective study was
undertaken during August–November 2009 on 71 malaria patients that fulﬁlled the inclusion criteria set by the WHO. Patients
were followed up for 28 days. Thick and thin blood ﬁlms were prepared by Giemsa stain for microscopy to determine parasite
density. A standard six-dose regimen of artemether-lumefantrine was administered over three days and was followed up with
clinical and parasitological evaluations over 28 days. Results. The cure rate (ACPR) was found to be high (97.2%) in this study. The
parasite and fever clearance time was also rapid. Artemether-lumefantrine for the treatment of acute uncomplicated Plasmodium
falciparummalariainthestudyareashowed97.2%curerateandonly2.8%failurerate.Conclusion.Theresultshowedthatthedrug
could continue as ﬁrst line for the treatment of uncomplicated Plasmodium falciparum malaria in the study area. The eﬃcacy of
artemether-lumefantrine needs to be carefully monitored periodically in sentinel sites representing diﬀerent areas of the country.
1.Introduction
Malaria is one of the major public health problems world-
wide causing more than one million deaths each year. It
is widespread in hot humid regions of Africa, Asia, and
South and Central America [1]. According to world health
organization (WHO) estimation, about 300–500 million
people are infected with malaria every year. More than 90%
of all malaria cases are in sub-Saharan Africa. Nearly 85% of
malaria is caused by Plasmodium falciparum and is responsi-
ble for about 90% of the deaths from malaria [2]. Malaria
has been consistently reported as one of the three leading
causes of morbidity and mortality in Ethiopia. Areas below
2000 meters above sea level are considered to be potentially
malarious [3]. Malaria-related morbidity and mortality has
been increasing in sub-Saharan Africa, primarily as a result
of increased resistance to the common ﬁrst line drugs—
chloroquine (CQ) and sulphadoxine-pyrimethamine (SP)
[4, 5]. Accordingly, the WHO recommends that treatment
policies for falciparum malaria in all countries experiencing
resistance to monotherapy should be combination therapies
containing artemisinin derivatives. Artemisinin antimalarial
drugs decrease parasite density more rapidly than other
antimalarial drug when used alone. The short half-life of
the artemisinin derivatives minimizes the period of parasite
exposure to subtherapeutic blood levels. Artemether reduces
parasitaemia, and lumefantrine eliminates residual parasites.
As the parasites are never exposed to artemether alone,2 Malaria Research and Treatment
this is thought to minimize the development of resistance
[6]. However, the wide spread use of artemisinin-based
combination therapies (ACTs) could have a major impact
on the treatment of malaria [7]. Widespread resistance of
malaria parasites to commonly available anti-malarial drugs
has necessitated countries to review and deploy new anti-
malarial drug policies to ensure eﬀective case management
[8]. Thus, this study aimed to evaluate the clinical and par-
asitological therapeutic eﬃcacy of artemether-lumefantrine
(AL) or Coartem against uncomplicated P. falciparum
malaria in Alamata district, North Ethiopia.
2. Patientsand Methods
2.1. Study Design and Population. A prospective study was
conducted in Alamata district, Tigrai regional state, North
Ethiopia, during August–November 2009. The sample size
was determined based on WHO standard protocol assuming
the anticipated population proportion of clinical failure of
20%, with 95% conﬁdence interval (PI), 10% precision, and
20% dropout, 73 patients were enrolled. Study subjects were
selected using convenient method as outlined in standard
protocol procedure [9]. Patients above 6 months of age,
slideconﬁrmedinfectionwithP.falciparum,initialdensityof
1000–100,000 asexual parasite/µL, and temperature ≥37.5◦C
were included. Patients with pregnancy, mixed infection,
infections other than malaria, history of allergy to drugs
tested,presenceofseveremalnutrition,dangersigns,andhis-
tory of hypersensitivity reactions to the drug were excluded.
P. falciparum positive cases were treated with 6 doses of AL
scaled by age/weight as outlined in the monogram of the
producer. AL was given as a tablet of 20mg of artemether
and120mgoflumefantrine(Novartis,Geneva,Switzerland).
All study participants were followed up for 28 days. Patients
who failed to respond to AL were treated with Quinine.
Patients were observed for at least 30min to ensure that
they do not vomit the drug. When vomiting occurred, the
full-treatment dose was repeated. The ﬁrst dose was given
on observation and the rest ﬁve doses taken at home under
the supervision of trained community health workers. Those
who agreed to participate in the study had informed to come
backduringthescheduledvisitforfollowupondays1,2,3,7,
14,21,28forbothclinicalandparasitologicalassessment.On
enrolment day, medical history of each patient was obtained.
2.2. Data Collection and Laboratory Procedures. The health
personnel involved in data collection was oriented on the use
of the study procedures designed by the WHO. Screening
was done by a health oﬃcer in an outpatient setting to
identify patients meeting the criteria. Data including age,
sex, address, and clinical ﬁndings (axillary temperature
of patients) during screening were retrieved. Blood was
collected for malaria smear examination. Patients who did
not meet these basic enrollment criteria were treated in
accordance with routine practice [10]. Finger prick blood
sample collection, preparation, and staining of blood slides
werethefollowedproceduresoutlinedinmalariamicroscopy
[11], using Giemsa staining at pH 7.2. The blood ﬁlms were
prepared for microscopy by a laboratory technician before
treatment on day 0 and on days 1, 2, 3, 7, 14, 21, and 28
that the patient was brought to the health center before the
next scheduled visit. Duplicate slides were prepared with
both thin and thick ﬁlm preparations using conventional
slides. One of the slides was used for rapid staining with 10%
Giemsa stain for 10–15 minutes and read while the patient
was in attendance. The second slide was used for subsequent
standard staining with 3% Giemsa stain for 30–45min.
This slide was used to determine parasite density. The ﬁrst
blood smear for screening was examined for the presence
of parasitaemia by counting the number of asexual parasites
and the number of white blood cells (WBCs) in limited
microscopic ﬁelds. Adequate parasitaemia for enrollment
requires at least 1 parasite/6–8 WBCs, which corresponds
to approximately 1000 asexual parasites/µL. The second
blood smear was examined to determine parasite density
and the number of asexual parasites per HPF according to
the method described in the WHO protocol. Parasitaemia
was measured by counting the number of asexual parasites
against a number of leucocytes in the thick blood ﬁlm,
based on a putative mean count of 8000 leucocytes per µL.
The number of asexual parasites was counted against 200+
leucocytesusingHandTallyCounter.Thus,parasitaemiawas
calculated using the formula [9]: Parasitaemia/µL = number
of Parasites × 8000/number of leucocytes. When 500+ para-
siteswereidentiﬁedbeforecounting200leucocytes,counting
wasstoppedandparasitaemiawascalculatedaccordingtothe
formula above. A blood slide was declared negative when the
examinationof100HPFdidnotshowthepresenceofasexual
forms of P. falciparum. Quality control was of microscopy
results of parasite counts that were made by cross-checking
10% of the total slides.
2.2.1. Deﬁnitions of Terms. Based on the WHO 2003 mod-
iﬁed protocol [12], the following deﬁnitions of therapeutic
responses are used.
Early treatment failure (ETF). It is the development of
danger signs for severe malaria on days 1, 2, or 3 in the
presence of parasitemia: parasitemia on day 2 higher than
day 0 count irrespective of axillary temperature; parasitemia
on day 3 with axillary temperature ≥37.5 ◦C; parasitemia on
day 3 ≥25% of count on day 0.
Late Clinical Failure (LCF). It is the development of danger
signs for severe malaria after day 3 in the presence of
parasitemia, without previously meeting any of the criteria
of ETF; presence of parasitemia and axillary temperature
≥37.5◦C or history of fever on any day from day 4 to day
28, without previously meeting any of the criteria of ETF.
Late Parasitological Failure (LPF). It is the presence of
parasitemia on any day from day 7 to day 28 and axillary
temperature <37.5◦C, without previously meeting any of the
criteria of early treatment failure or late clinical failure.Malaria Research and Treatment 3
Adequate Clinical and Parasitological Response (ACPR). It is
the absence of parasitemia on day 28 irrespective of axillary
temperature without previously meeting any of the criteria
of ETF, LTF, or LPF. The secondary outcomes were fever
clearance rate; proportion of patients who have fever cleared
at day 1, 2, and 3. Parasite clearance rate: proportion of
patients with negative thick blood ﬁlm smears on days 1,
2, and 3. Gametocyte carriage: proportion of patients with
gametocytes during the course of the study.
FeverClearanceTime(FCT). Itwasdeﬁnedasthetimefrom
drug administration until the body temperature decreased to
<37.5◦C and remained so for 48 hours.
Parasite Clearance Time (PCT). I tw a sd e ﬁ n e da st h et i m e
from drug administration until the ﬁrst in series of negative
blood smears.
Parasite Resistance. It was deﬁned as the ability of a parasite
strain to survive and/or multiply despite the administration
and absorption of a drug in doses equal to or higher than
those usually recommended but within the limits of toler-
ance of the subject.
2.3. Ethical Considerations. The therapeutic eﬃcacy test was
conducted under supervision of qualiﬁed medical oﬃcer.
EthicalclearanceswereobtainedfromTigraiRegionalHealth
Bureau and Institutional Review Board (IRB) of the Medical
School of Addis Ababa University. Informed written con-
sent was obtained from all eligible participants/parents or
guardians of under 18 years of age children.
2.4. Data Analysis. Data were analysed using SPSS for Win-
dows, version 15. Descriptive statistics as percentages, mean,
median, standard deviation, and range were applied as
appropriate. The eﬃcacy assessment was done by modiﬁed
intention to treat (ITT) and per protocol (PP) analysis. The
ITT population was used for analysis of variables, primary
and secondary eﬃcacy end points. The PP employed Kaplan
Meir used for analysis of primary outcomes (ETF, LCF, LPF,
and ACPR). Bivariate analysis was used to compare means.
Forallstatisticalteststhesigniﬁcancelevel(P)wassetat0.05.
3. Results
3.1. Characteristics of the Study Population. A total of 303
patients with fever were screened for malaria. Of these, 107
(35.3%) were positive for plasmodium species of which 77
(72%) were with P. falciparum and 30 (28%) P. vivax. Of
the 77 patients with P. falciparum infection, 73 (94.8%)
fulﬁlled the inclusion criteria set by WHO. Of the 73 cases,
two patients were lost to in the followup on days 1 and 7.
Thus, 71 patients were successfully followed up in the course
of the study. The age group 5–15 years represented most
patients, 30 (41.1%) followed by the group >15 years of age
29 (39.7%) (Table 1). The smallest age group was the under
5 years 14 (19.2%). The median age of the study population
was 14 years (2–70 years), and the majority 45 (61.6%) of
Table 1: Baseline characteristics of the study population at Tumuga
Health Center, Alamata, November 2009.
Variables Value
Sex
Female, no. (%) 26 (36.6)
Age (years)
Mean 15.2
Median 14
Range 2–70
No. (%)
<5 13 (18.3)
5–15 30 (42.3)
>15 28 (39.4)
Body weight (kg)
Mean 36.2 ± 17.3
Range 9–74
Temp (◦C), mean 38.2
Parasite count
Mean density (ring/µL) 20,672
Rate (%) 35.3
the study cases were males. The mean body weight was 36.2
± 17.3kg (range: 9–74kg). On recruitment, 64/71 (90.1%)
of the patients receiving AL had body temperature >37.6◦C.
The mean temperature and parasite count were 38.2◦Ca n d
20,672 rings/µL, respectively.
3.2. Parasitaemia, Fever/Parasite Clearance Time, and Treat-
ment Responses. The association between initial parasite
density at recruitment and length of parasite clearance time
was signiﬁcant (P = 0.030) (Tables 2 and 3). Concerning
the fever clearance time and parasite density at day 0, no
signiﬁcant association was found (P = 0.067) (Table 3).
Clinical failure (LCF) was 2.8% observed on day 21 and
day 28, 1.4% LCF on each days. The cure rate (ACPR) was
97.2% on the study site and the parasite clearance is rapid
and complete clearance of parasitaemia within 32 hours
was observed in all (100%) patients. The mean parasite
clearance time (PCT) was 26.5 ± 2.3hrs. Proportion of
patients with gametocytes at enrolment was 1.4% by day 7.
Fromday14onwards,nopatienthadgametocytes.Feverand
parasiteclearedrapidlyover32hoursafterstartingtreatment
(Table 4). Therefore all, (100%) patients had cleared fever
after 32 hours. The rate of parasite clearance was 100%
after 32 hours of starting treatment and patients were no
longer parasitaemic by day 2. No major adverse events were
observedthroughoutthe28daysfollowup.TheKaplanMeier
survival analysis of the data showed estimates of success of
1.00 from day 0 to 20, 0.986 from day 21 to 27 and 0.972
on day 28. The estimate of failure cumulative incidence was
0.00 from day 0–20, 0.014 from day 21–27, and 0.028 on day
28. The proportion of success and failure of patients at each
point in time is not signiﬁcant as the (95%CI, 0.933–1.010)
and (0.067–0.010), respectively. Thus, the estimate of success
(cure) rate was 97.2% and estimate of failure was 2.8%4 Malaria Research and Treatment
Table 2: Temperature at recruitment versus mean parasite and fever clearance time at Tumuga Health Center, Alamata, November 2009.
Temperature (◦C) day 0 Mean PCT P value Mean FCT P value
≤37.0 25.43 25.57
37.1–37.5 29.00 29.50
37.6–38 26.52 26.00
38.1–39 26.61 26.32
≥39.1 26.00 25.00
Total 26.47 0.392 26.08 0.178
PCT: parasite clearance time; FCT: fever clearance time.
Table 3: Parasite densities at day 0 versus mean parasite and fever clearance time at Tumuga Health Center, Alamata, November 2009.
Parasite density day 0 Mean PCT P value Mean FCT P value
1000–11000 25.53 25.20
11001–21000 26.93 26.47
21001–31000 26.90 26.80
31001–41000 27.38 26.50
41001–51000 29.00 28.40
51001–61000 26.00 27.00
>61000 25.67 25.00
Total 26.47 0.030 26.08 0.067
Table 4: Parasite counts at recruitment, parasite clearance time and fever clearance time at Tumuga Health Center, Alamata, November,
2009.
Parasite count per micro liter blood Parasite clearance time (hrs) Fever clearance time (hrs)
Mean 20672 26.5 26.0
Median 14800 26.0 25.0
SD 47295 2.3 2.4
Range 1440–73920 9.0 8.0
Minimum 1440 23.0 24.0
Maximum 73920 32.0 32.0
during the 28 days followup. In the intent to treat analysis,
the lost to followup were included in the denominator of the
study analysis, but were excluded in the per-protocol analysis
approach.Thestudyoutcomesbyfollow-updaysshowed0%
on day 7 and day 14, but 1.4% LCF on day 21 and 2.8% LCF
by day 28. The ACPR was 100% on day 7 and day 14 but
98.6% on day 21 and 97.2% on day 28 (Table 5).
4. Discussion
AL treatment failure was 0% after 14 days and 0.09% after 28
days followup in the ﬁrst line treatment of uncomplicated P.
falciparum malaria at national level [12]. The present study
showed that the standard six-dose of AL ﬁrst line treatment
was eﬀective against uncomplicated P. falciparum malaria
with rapid clearance of fever and parasitaemia and cure rate
of 97.2% in 28 days. According to the Kaplan Meier survival
analysis, the data obtained was 0.972 (95%CI, 0.933–1.010)
showing the eﬀectiveness of the drug. The failure cumulative
incidence was 0.028 (95%CI, 0.067–0.010). The ﬁnding
97.2% of adequate clinical and parasitological response
(ACPR)isconsistentwiththetherapeuticeﬃcacystudydone
in the country during deployment of the drug in 2004. The
aggregated mean of clinical and parasitological treatment
response to AL was 100% and 99.01% (PCR unadjusted)
for 14 and 28 days followup, respectively. In addition the
study showed consistency with other therapeutic eﬃcacy
studies with 100% adequate clinical and parasitological
response [13]. Another study on therapeutic eﬃcacy of AL
for the treatment of uncomplicated P. falciparum malaria
in rural endemic area of Ethiopia showed PCR unadjusted
ACPR of 95.8% and 96.2%, respectively, and the PCR
corrected ACPR in the two sites was 96.8% and 97.4%,
respectively [14]. Our study results had shown 97.2% ACPR
without PCR correction. This is much higher than the study
done in African children where they found 86.5% ACPR
without PCR correction [15]. The higher eﬃcacy of AL
in this study may be due the relatively shorter period of
deployment. Another study conducted in Zambia, which
assessed therapeutic eﬃcacy of a pediatric formulation of
AL for the treatment of uncomplicated malaria in children
less than 10kg in 2005 was same ACPR after 28 days
followup(100%PCRcorrectedbut96.0%PCRuncorrected)Malaria Research and Treatment 5
Table 5: Classiﬁcation outcomes by follow-up days in percent at
Tumuga Health Center, Alamata, November 2009.
Outcome Day 7 % Day 14 % Day 21 % Day 28 %
ETF 0 0 0 0
LCF 0 0 1.4 2.8
LPF 0 0 0 0
ACPR 100 100 98.6 97.2
ETF; Early treatment failure, LCF; Late clinical failure, LPF; late Parasito-
logical failure; TTF; total treatment failure; ACPR; Adequate clinical and
parasitological response.
[16]. A study conducted in India in 2006 also showed
a cure rate of 100% (PCR corrected) in the treatment
of uncomplicated P. falciparum malaria with six-dose AL
regimen [17]. Our study showed fast parasite clearance time
withmeantimeof26.5hrsandgoodcomplianceduetoﬁxed
dose combination and short treatment duration. The failure
to adherence in this study was 2 (2.7%).The fast parasite
and fever clearance is due to the rapidly absorbed and its
main active metabolite dihydroartemisinin (DHA) achieve a
fast reduction in parasite biomass and prompt symptomatic
improvement, while the lumefantrine concentrations that
persist in the blood after the three days treatment course
eliminate any remaining parasites to prevent recrudescence
[18].
The proportion of female patients was found low
(38.4%) in the study group compared with male patients
(61.6%). The proportion of female patients was found 30%
in a study done in two study sites in Zambia with 49% and
54.6%[16].Inastudyconductedamongchildren<5y ear sin
Eastern Sudan, the proportion of female patients was 31.8%
[19]. The low proportion of female patients in our study may
berelatedtodiﬀerenceinhealthseekingbehaviorratherthan
diﬀerence in disease prevalence.
The mean temperature of the patients on day 0 was
38.2◦C+0.86. Similar mean temperature 38.5◦C ± 0.6 was
reported from Sudan [19] and 38.7◦Cf r o mZ a m b i a[ 16].
In our study, the mean fever clearance and parasite clear-
ance times were 26 and 26.5 hours, respectively. In a study
conducted in 2003 for the eﬃcacy of AL for uncomplicated
malaria, fever clearance and parasite clearance time were 47
and 36 hours, respectively [20]. In another study, the median
fever clearance time was 24 hours and the median parasite
clearance time 48 hours [21]. In our study the median fever
clearance and parasite clearance time were 25 and 26hrs,
respectively. The variation of fever and clearance time in
diﬀerent areas may be due to diﬀerences in parasite density
at day 0. It may also be due to diﬀerences in times of the
drug deployments in the diﬀerent regions. Generally, the
fever clearance time was fast because the drug has antipyretic
property and the drug is fast acting on diﬀerent stages of
the parasite which makes the parasite clearance time shorter
[18].
Bivariate analysis showed that the only base line char-
acteristic that aﬀected parasite clearance time was para-
site density at day 0. There was an association between
the mean parasite clearance time and parasite density
(P = 0.030). This was because of the higher density of
the parasite at day 0 which prolongs the parasite clearance
time [19]. Regarding with temperature at recruitment and
clearance time association, it was not found to be signiﬁcant
(P = 0.392 and 0.178) and this may be due to uses of
antipyretic drug like paracetamol. Similarly, there was no
association between parasite density at day 0 and fever
clearance time (P = 0.067) for the same reasons mentioned
above.
Limitations. The study was conducted without fat intake.
This may have impact in reduced absorption of the drug.
In conclusion, AL was safe and eﬀective drug for the
treatment of uncomplicated falciparum malaria in the study
area 5 years after the deployment of the drug. This highly
eﬃcacious drug showed rapid fever and parasite clearance
and the eﬃcacy (97.2%) met the WHO criteria for eﬃcacy
(>95%) in malaria endemic regions. The eﬃcacy of this
ACT needs to be carefully monitored periodically since the
t r e a t m e n tf a i l u r e sc a no c c u rd u et or e s i s t a n c ea sw e l la s
subtherapeutic levels due to inadequate absorption or low
adherence to the drug. For better absorption, the drug may
be administered after diet with fat.
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